Drug analysis: C-Cure

  • ID: 4462138
  • Drug Pipelines
  • 15 pages
  • Datamonitor Healthcare
1 of 3
Drug Overview

C-Cure is a bone marrow-derived stem cell therapy aimed at regenerating cardiac tissue following severe damage due to myocardial infarctions. C-Cure consists of a patient’s own cells harvested from bone marrow, which are treated with Celyad’s proprietary cell culture to form autologous heart muscle cells. These cells are then re-injected directly into the scar tissue of the patient’s heart to repopulate the damaged areas and improve cardiac function.
Note: Product cover images may vary from those shown
2 of 3
Product Profiles
C-Cure: Chronic heart failure (CHF)

List of Figures
Figure 1: C-Cure for chronic heart failure - SWOT analysis
Figure 2: Drug assessment summary of C-Cure for chronic heart failure
Figure 3: Drug assessment summary of C-Cure for chronic heart failure
Figure 4: C-Cure sales for chronic heart failure across the US, Japan, and five major EU markets, by country, 2017-26

List of Tables
Table 1: C-Cure drug profile
Table 2: C-Cure’s proposed Phase III trial design in chronic heart failure
Table 3: C-Cure completed late-phase data in chronic heart failure
Table 4: C-Cure sales for chronic heart failure across the US, Japan, and five major EU markets, by country ($m), 2017-26
Note: Product cover images may vary from those shown
3 of 3

Loading
LOADING...

4 of 3
Note: Product cover images may vary from those shown
Adroll
adroll